Gradishar William J
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cancer Manag Res. 2016 Jul 11;8:85-94. doi: 10.2147/CMAR.S98249. eCollection 2016.
Community-based oncologists are faced with challenges and opportunities when delivering quality patient care, including high patient volumes and diminished resources; however, there may be the potential to deliver increased patient education and subsequently improve outcomes. This review discusses the treatment of postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2- negative advanced breast cancer in order to illustrate considerations in the provision of pertinent quality education in the treatment of these patients and the management of therapy-related adverse events. An overview of endocrine-resistant breast cancer and subsequent treatment challenges is also provided. Approved treatment options for endocrine-resistant breast cancer include hormonal therapies and mammalian target of rapamycin inhibitors. Compounds under clinical investigation are also discussed.
社区肿瘤学家在提供高质量患者护理时面临挑战和机遇，包括患者数量众多和资源减少；然而，有可能提供更多的患者教育并随后改善治疗结果。本综述讨论了绝经后内分泌抵抗、激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌的治疗，以说明在为这些患者提供相关优质教育以及治疗相关不良事件管理方面的考虑因素。还提供了内分泌抵抗性乳腺癌及其后续治疗挑战的概述。内分泌抵抗性乳腺癌的批准治疗选择包括激素疗法和雷帕霉素靶蛋白抑制剂。还讨论了正在进行临床研究的化合物。
